Genomics and health innovation ETFs in the biology trade
Gene editing, gene sequencing and health technology companies. Driven by progress from trial to approved therapy, and what it costs them to raise money.
13ETFs in this category
$3.6bnmoney in them
2.8%of the biology trade’s money
ARKGlargest unleveraged ETF, 65.5%
How they did, to Nov 2, 2026
| 1 month | YTD | 12 months | |
|---|---|---|---|
| Category median | −0.3% | +24.4% | +36.4% |
| Its story | +7.5% | +21.0% | +29.0% |
| Broad US ETFs | −2.5% | +11.5% | +11.8% |
Every ETF here, largest first
| # | ETF | Name | Assets | Share | 12 months | Fee |
|---|---|---|---|---|---|---|
| 1 | ARKG | ARK Genomic Revolution ETF | $2.4bn | 65.5% | +55.1% | 0.75% |
| 2 | PBE | Invesco Biotechnology & Genome ETF | $446m | 12.3% | +37.3% | 0.59% |
| 3 | IDNA | iShares Genomics Immunology & Healthcare ETF | $338m | 9.3% | +66.1% | 0.47% |
| 4 | LFSC | F/m Emerald Life Sciences Innovation ETF | $125m | 3.5% | +31.6% | 0.54% |
| 5 | GNOM | Global X Genomics & Biotechnology ETF | $118m | 3.2% | +49.1% | 0.50% |
| 6 | HTEC | Robo Global Healthcare Technology and Innovation ETF | $115m | 3.2% | +36.4% | 0.68% |
| 7 | HELX | Franklin LibertyQ Genomic Advancements ETF | $37m | 1.0% | +24.1% | 0.50% |
| 8 | HEAL | Global X HealthTech ETF | $36m | 1.0% | −2.9% | 0.50% |
| 9 | BMED | iShares Health Innovation Active ETF | $15m | 0.4% | +26.9% | 0.55% |
| 10 | HLTH | Tema Healthcare AI ETF | $13m | 0.3% | – | 0.75% |
| 11 | WDNA | WisdomTree BioRevolution Fund | $5m | 0.1% | +44.0% | 0.45% |
| 12 | LGHT | Langar Global Healthtech ETF | $2m | 0.0% | +7.3% | 0.85% |
| 13 | GNMX | Corgi Genomics & Precision Medicine ETF | $1m | 0.0% | – | 0.35% |
Other categories in the biology trade
Common questions
Which ETFs are genomics and health innovation ETFs?13 US ETFs sit in this category of the biology trade. Gene editing, gene sequencing and health technology companies. Driven by progress from trial to approved therapy, and what it costs them to raise money.
What is the largest genomics and health innovation ETF?ARKG, ARK Genomic Revolution ETF, with $2.4bn, 65.5% of the category's money.
How have genomics and health innovation ETFs performed?The median unleveraged ETF here returned +36.4% over the last 12 months to Nov 2, 2026, against +11.8% for broad US ETFs. Past performance, not a forecast.